Fedratinib for patients with myelofibrosis - Authors' reply
- PMID: 40174996
- DOI: 10.1016/S2352-3026(25)00010-9
Fedratinib for patients with myelofibrosis - Authors' reply
Conflict of interest statement
CNH receives research funding from Bristol Myers Squibb, Constellation–Morphosys, and Novartis; consulting fees from Galecto, Geron, and GlaxoSmithKline; honoraria from AbbVie, AOP Health, Bristol Myers Squibb–Celgene, CTI BioPharma, Galacteo, Geron, Gilead, IMAGO, Janssen, Keros, Novartis, Promedior, Roche, Shire, and Sierra; is on a data safety monitoring board or advisory board for Galacteo and Keros; and in a leadership position at the European Hematology Association. PB is employed by and holds stock or stock options in Bristol Myers Squibb. J-JK receives consulting fees from AbbVie and GlaxoSmithKline; honoraria from AOP Health and Novartis; and is on a data safety monitoring board or advisory board for Bristol Myers Squibb and Incyte.
Comment on
-
Fedratinib for patients with myelofibrosis.Lancet Haematol. 2025 Apr;12(4):e240. doi: 10.1016/S2352-3026(24)00398-3. Lancet Haematol. 2025. PMID: 40174994 No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources